Category Archives: Cf

LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced it has reached a new portfolio agreement with the Italian Medicines Agency, AIFA, for the reimbursement of all of Vertexs approved medicines for the treatment of cystic fibrosis (CF), including KAFTRIO (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor.

Italian patients ages 12 years and older with one F508del mutation and one minimal function mutation (F/MF) or two F508del mutations (F/F) in the cystic fibrosis transmembrane conductance regulator (CFTR) gene will now have access to KAFTRIO (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor. Additionally, under the terms of the agreement, eligible patients ages two years and older with CF who have two copies of the F508del mutation in the CFTR gene (F/F) will now have access to ORKAMBI (lumacaftor/ivacaftor). Eligible patients ages 12 years and older who either have two copies of the F508del mutation (F/F), or one copy of the F508del mutation and another responsive residual function mutation in the CFTR gene (F/RF), will have broad access to SYMKEVI (tezacaftor/ivacaftor) in combination with ivacaftor. The agreement also expands access to KALYDECO (ivacaftor) for eligible patients ages one year and older. In addition, the agreement covers any new approved indication extensions for Vertexs CF medicines submitted and approved for reimbursement during the term of the contract.

Ludovic Fenaux, Senior Vice President, Vertex International, commented, This agreement is an important milestone for cystic fibrosis patients in Italy. Our medicines have fundamentally changed the way CF is treated, and we are delighted with this broad portfolio agreement which includes access for younger patients to ORKAMBI and KALYDECO and access to SYMKEVI and KAFTRIO for patients 12 years and older. I would like to thank AIFA and all parties involved for their collaboration, commitment and engagement in quickly reaching this agreement.

KALYDECO was first reimbursed in Italy in 2015, followed by ORKAMBI in 2017 for patients 12 years and older. Vertexs CF medicines are reimbursed in over 25 countries around the world including Australia, France, Germany, the Republic of Ireland, the Netherlands, Spain, Sweden, the U.K. and the U.S.

About KAFTRIO (ivacaftor/tezacaftor/elexacaftor) in a Combination With Ivacaftor

KAFTRIO (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor 150 mg was developed for the treatment of cystic fibrosis (CF) in patients ages 12 years and older who have at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Ivacaftor/tezacaftor/elexacaftor is designed to increase the quantity and function of the F508del-CFTR protein at the cell surface. The latest approved EU licensed indication for ivacaftor/tezacaftor/elexacaftor was supported by positive results of three global Phase 3 studies in people ages 12 years and older with CF: a 24-week Phase 3 study (Study 445-102) in 403 people with one F508del mutation and one minimal function mutation (F/MF), a four-week Phase 3 study (Study 445-103) in 107 people with two F508del mutations (F/F), and a Phase 3 study (Study 445-104) in 258 people heterozygous for the F508del-CFTR mutation and a CFTR gating mutation (F/G) or a residual function mutation (F/RF).

For complete product information, please see the Summary of Product Characteristics that can be found on http://www.ema.europa.eu.

About SYMKEVI (tezacaftor/ivacaftor) in Combination With Ivacaftor

Some mutations result in CFTR protein that is not processed or folded normally within the cell, and that generally does not reach the cell surface. Tezacaftor is designed to address the trafficking and processing defect of the CFTR protein to enable it to reach the cell surface and ivacaftor is designed to enhance the function of the CFTR protein once it reaches the cell surface.

For complete product information including dosing guidance, please see the Summary of Product Characteristics that can be found on http://www.ema.europa.eu.

About ORKAMBI (lumacaftor/ivacaftor) and the F508del Mutation

In people with two copies of the F508del mutation, the CFTR protein is not processed and trafficked normally within the cell, resulting in little-to-no CFTR protein at the cell surface. Patients with two copies of the F508del mutation are easily identified by a simple genetic test.

Lumacaftor/ivacaftor is a combination of lumacaftor, which is designed to increase the amount of mature protein at the cell surface by targeting the processing and trafficking defect of the F508del-CFTR protein, and ivacaftor, which is designed to enhance the function of the CFTR protein once it reaches the cell surface.

For complete product information, please see the Summary of Product Characteristics that can be found on http://www.ema.europa.eu.

About KALYDECO (ivacaftor)

Ivacaftor is the first medicine to treat the underlying cause of CF in people with specific mutations in the CFTR gene. Known as a CFTR potentiator, ivacaftor is an oral medicine designed to keep CFTR proteins at the cell surface open longer to improve the transport of salt and water across the cell membrane, which helps hydrate and clear mucus from the airways.

For complete product information, please see the Summary of Product Characteristics that can be found on http://www.ema.europa.eu.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) a rare, life-threatening genetic disease and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of cell and genetic therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.

Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 11 consecutive years on Science magazine's Top Employers list and a best place to work for LGBTQ equality by the Human Rights Campaign.

Special Note Regarding Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements made by Ludovic Fenaux, Senior Vice President, Vertex International, in this press release and statements regarding our beliefs about the eligible patient population that will have access to our medicines, including patients that will now have access to a CFTR modulator for the first time, reimbursement coverage for future approved indication extensions of our medicines, and our beliefs regarding the benefits of our medicines. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those indicated by such forward-looking statements. Those risks and uncertainties include, among other things, that data from the companys development programs may not support an extended indication for our medicines, and other risks listed under the heading Risk Factors in Vertex's annual report and in subsequent filings filed with the Securities and Exchange Commission and available through the company's website at http://www.vrtx.com and http://www.sec.gov. You should not place undue reliance on these statements. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.

(VRTX-GEN)

Link:

Vertex Announces New Portfolio Reimbursement Agreement in Italy Including KAFTRIO, SYMKEVI and Additional Indications of ORKAMBI and KALYDECO for...

CF Industries Holdings, Inc.s CF shares have gained 29.1% so far this year. The company has also outperformed its industrys rise of 19.7% over the same time frame. Moreover, it has topped the S&P 500s 12.4% rise over the same period.

Lets take a look into the factors behind this Zacks Rank #1 (Strong Buy) stocks price appreciation.

Zacks Investment Research

Image Source: Zacks Investment Research

Strong demand of nitrogen fertilizer, higher nitrogen prices and upbeat outlook have contributed to the rally in the companys shares.

CF Industries is benefiting from higher nitrogen prices as witnessed in the first quarter of 2021. The companys average selling prices in the quarter were higher on a year-over-year basis across most segments due to lower global supply availability.

The company expects nitrogen pricing to be positive in 2021 as global nitrogen supply and demand balance has been significantly tightened by low global coarse grains stocks-to-use ratios as well as higher energy prices in Asia and Europe. As such, higher nitrogen prices are expected to drive the companys sales and bottom line.

Moreover, CF Industries should gain from higher nitrogen fertilizer demand in major markets. Global nitrogen demand is expected to remain strong this year. Strong crop commodity prices are contributing to higher demand globally. Industrial demand has also recovered from the pandemic-related disruptions.

The company, in its first-quarter call, said that it sees around 90-92 million planted corn acres in the United States in 2021. It also expects higher canola plantings in Canada to support nitrogen demand. Moreover, CF Industries projects higher nitrogen demand in North America for industrial uses. The company anticipates nitrogen requirements in other regions to remain strong this year, which is likely to be driven by strong demand for urea imports from India and Brazil.

Story continues

CF Industries Holdings, Inc. Price and Consensus

CF Industries Holdings, Inc. price-consensus-chart | CF Industries Holdings, Inc. Quote

Other top-ranked stocks worth considering in the basic materials space include Nucor Corporation NUE, Cabot Corporation CBT and Impala Platinum Holdings Limited IMPUY.

Nucor has a projected earnings growth rate of 285.3% for the current year. The companys shares have surged around 123% in a year. It currently sports a Zacks Rank #1. You can see the complete list of todays Zacks #1 Rank stocks here.

Cabot has an expected earnings growth rate of around 126% for the current fiscal. The companys shares have rallied 55% in the past year. It currently carries a Zacks Rank #2 (Buy).

Impala Platinum has an expected earnings growth rate of 225.2% for the current fiscal. The companys shares have surged around 137% in the past year. It currently carries a Zacks Rank #2.

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

You know this company from its past glory days, but few would expect that its poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.

Free: See Our Top Stock and 4 Runners Up >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Nucor Corporation (NUE) : Free Stock Analysis Report

CF Industries Holdings, Inc. (CF) : Free Stock Analysis Report

Cabot Corporation (CBT) : Free Stock Analysis Report

Impala Platinum Holdings Ltd. (IMPUY) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Read more:

CF Industries (CF) Stock Up 29% YTD: What's Driving the Rally? - Yahoo Finance

The first participants have been dosed in the first clinical trial testing EDT001, an investigational therapy for cystic fibrosis (CF) being developed by Enterprise Therapeutics.

The trial is being conducted in healthy participants (without CF) to assess the investigational medicines safety profile.

We are excited to be entering the clinic with ETD001, John Ford, PhD, Enterprises CEO, said in a press release.

CF is caused by mutations in the CFTR gene that provides instructions for making the CFTR protein, which regulates the transport of water and salts in and out of cells. One of the hallmark consequences of CFTR dysfunction in CF is the formation of abnormally thick mucus, which impairs the function of the lungs and other organs, and provides a breeding ground for infectious bacteria.

ETD001 is designed to target a protein called epithelial sodium ion channel, or ENaC. Like the CFTR protein, ENaC helps to coordinate the amount of water and other substances present in mucus.

By targeting ENaC, EDT001 aims to increase the amount of water in the mucus, making it less thick. This could improve lung function and life quality, and reduce the frequency of lung infections, in people with CF.

According to Ford, EDT001 has best-in-class potential due to its long duration of action in the lung and favourable pre-clinical safety profile.

The investigational therapy could significantly improve quality of life for people living with cystic fibrosis and other respiratory diseases linked to mucus obstruction, Ford said.

Notably, because it targets the ENaC protein, EDT001 is expected to work equally well in all people with CF, regardless of which type of CFTR mutation they have. This sets EDT001apart from other CF treatments, such as CF modulators a therapy class that works to correct the function of the CFTR protein in people with specific mutations.

ENaC inhibition via ETD001 shows great promise in providing a therapeutic option for the many people with cystic fibrosis who are not genetically suited to or fail to benefit from CFTR modulators, said David Morris, MD, chief medical officer at Enterprise.

We look forward to generating our first data in human volunteers under this program, Morris said.

Originally posted here:

Healthy Participants Dosed in Trial of Investigational CF Therapy EDT001 - Cystic Fibrosis News Today

MIAMI (CBSMiami) Inter Miami CF midfielder Lewis Morgan sat down for an interview with CBS4 Mike Cugno, to speak about the current season and what the team needs to do to improve.

Q: I saw in an interview your bucket list item is to go sky diving. So, lets start there. Have you been able to jump out of a plane yet?

A: No not yet. I dont actually know how the football club would take me doing that at the moment. So yea just a lot of golf at the moment in my spare time. Ill have plenty of time for sky diving once I hang up the boots.

Morgan hasnt taken that big leap of faith just yet. But he dove right into a young franchise and became a household name last year, scoring 5 goals and recording 8 assists. He earned team MVP honors.

Q: Were you surprised or you just knew you had that in you and you were ready for a big year?

A: I think thats probably a good way to put it I was definitely ready for a big year. I had a couple of years of not disappointments as such but maybe frustrations of not playing at levels I knew I was capable of. It was something when I signed with the club it was a goal that I had in mind. Its a goal that I have, not just as a year objective, but every day in training I want to be the best player.

Now, as one of the best players for the club, Morgan has to identify why theyve gotten off to a slow start, losing 4 of their first 8 matches of their second season. He says talent is there but theattitude has to follow.

What are we like when the game goes against us? And recently when weve maybe had a setback we havent really bounced back having won. These little things that we are trying to help to do better and Ive seen a great reaction from the team. We obviously had a bounce-back game behind closed doors against Toronto and the guys looked great. Its just about taking our training performances into games and really having that belief, said Morgan.

As Morgan mentioned, Inter Miami recently beat Toronto in a closed-door scrimmage. Theyre hoping to use that as a jumping-off point for the next part of their season.

Having these few weeks to really focus on improving and taking what we achieved in the first 8 games of the season, the games weve done well in, and why weve done well in those games and try to replicate that going forward. I think weve made the best use of the time afforded to us and I think were just looking forward to getting back to the games and hopefully righting some wrong of the previous DC game.

Read more from the original source:

Inter Miami CF Midfielder Lewis Morgan On The Need To Improve - CBS Miami

The 60 rating InvestorsObserver gives to CF Industries Holdings, Inc. (CF) stock puts it near the top of the Agricultural Inputs industry. In addition to scoring higher than 78 percent of stocks in the Agricultural Inputs industry, CFs 60 overall rating means the stock scores better than 60 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

CF Industries Holdings, Inc. (CF) stock is trading at $48.86 as of 1:38 PM on Friday, Jun 18, a drop of -$1.15, or -2.3% from the previous closing price of $50.01. The stock has traded between $48.67 and $50.15 so far today. Volume today is 1,653,255 compared to average volume of 2,111,996.

Click Here to get the full Stock Score Report on CF Industries Holdings, Inc. (CF) Stock.

Read the original here:

Is CF Industries Holdings, Inc. (CF) Stock at the Top of the Agricultural Inputs Industry? - InvestorsObserver

RCT223 and RTX0001, ReCode Therapeutics experimental RNA-based therapies for cystic fibrosis (CF), safely restored function to CFTR, the faulty protein in CF, in patient-derived lung cells.

Delivered through the companys non-viral platform called the selective organ targeting (SORT) lipid nanoparticle (LNP) platform the therapies were also found to be well-tolerated in lung cells from patients and in mice.

Our RNA-based approaches and broad LNP platform enable us to tackle CF from multiple angles in order to specifically target the underlying causes of the disease and maximally help patients, David Lockhart, PhD, ReCodes CEO and president, said in a press release.

These data showcase the potential of our differentiated RNA-based molecular therapies to treat cystic fibrosis, Lockhart said, adding that they are an important step as the company advances its CF program closer to studies in people.

ReCode plans to apply to the U.S. Food and Drug Administration in 2022, seeking the agencys clearance to start clinical trials of these therapies in the U.S.

The preclinical findings were presented by Michael Torres, PhD, the vice president of Recodes research and development, at the 44th European Cystic Fibrosis Conference held virtually June 912.

The oral presentation was titled Rescue of CFTR function in primary bronchial epithelial cells from patients with cystic fibrosis using lipid nanoparticle delivery of RNA-based therapies.

In people with CF, mutations in the CFTR gene impair the production of a functional CFTR, a protein channel that controls the flow of water and salts through cells, triggering the mucus in various organs to become thick and sticky.

ReCodes CF program, supported by a grant from the Cystic Fibrosis Foundation, is focused on treating the 1013% of CF patients who have nonsense mutations and limited therapeutic options.

Nonsense mutations introduce a premature stop signal in CFTRs DNA sequence, leading to the production of a shorter, non-functional CFTR protein.

The CF program currently comprises two RNA-based therapies delivered through the companys SORT LNP platform, which uses tiny non-viral fat (lipid) particles to transport and deliver their cargo to targeted organs.

The companys lead candidate, RCT223, uses a transfer RNA (tRNA) molecule which plays a role in the process of protein production to replace the premature stop signal with a go sequence in the CFTR gene, so that the full CFTR protein can be produced.

Newly presented data showed that both single and repeated dosing of RCT223 restored CFTR function in lung cells derived from CF patients and grown in the lab, a gold-standard cell model of CF.

This effect lasted for at least 72 hours (three days) after a single administration, and CFTR functional levels continued to rise with twice-weekly doses.

ReCodes mRNA replacement agent for CF, RTX0001, is designed to deliver to cells a working version of CFTRs messenger RNA molecule (mRNA), the intermediate molecule derived from DNA that guides protein production.

As such, RTX0001 is expected to increase the production of a working CFTR protein.

Preclinical data showed that RTX0001, delivered through a commercially available mesh nebulizer, successfully delivered CFTRs healthy mRNA into patient-derived lung cells and into the lungs of mice.

The delivered mRNA was found to effectively and significantly increase the production of a working CFTR after a single, low dose, and CFTRs activity was sustained for at least 72 hours after twice-weekly administration.

Both RNA-based therapies were generally well-tolerated in the evaluated preclinical models.

By leveraging our LNP platform to deliver genomic medicines, we have demonstrated the ability to restore cystic fibrosis transmembrane conductance regulator (CFTR) function through both tRNA and mRNA approaches, Lockhart said.

The companys pipeline also includes potential RNA-based therapies for primary ciliary dyskinesia (PCD), a genetic condition that impairs the function of lung cilia the fingerlike projections in the airways leading to chronic respiratory infections.

ReCode raised $80 million to support the preclinical development of its CF and PCD programs in April 2020.

See the rest here:

RNA-based Therapies Show Promise in Early Studies, ReCode Reports - Cystic Fibrosis News Today

CARTHAGE, Mo. After nearly two years a 12-year-old girl with Cystic Fibrosis is getting her wish granted.

Paige Talbotts family is celebrating her new backyard makeover.

Paige Talbott, Wish Granted, says, I spent the night out here about twice already.

Paige Talbott was diagnosed with Cystic Fibrosis when she was two weeks old.

In November 2019, she asked Make A Wish Foundation for a trip to Hawaii, but Coronavirus changed her plans.

Chad Baker, Wish Granter with Make A Wish Missouri and Kansas, says, With Covid and having to redirect travel she changed her mind and wanted a space to play games and a space to her and her family to hangout.

So Make A Wish started renovating the backyard in February taking out trees and leveling the ground.

Ozark installation leveled their yard, and Lowes came in with a new fence.

They added a soccer net and volleyball net so she had a safe space to play with family and friends.

Paige also has a shed complete with furniture, air conditioning, refrigerator and a tv.

I feel happy, because I can use this a lot more.

We can be away from parents. Its like my own house. Except I dont really have to pay for anything still.

its like I have a normal life, without CF.

This is one of the first times over the past two years that Paige has been able to hangout with friends and family.

Chelsea Talbott, Paiges Mom, says, Seeing Paige come out of her shell and want to play volleyball and not be in a state of a bit of depression because she had to isolate and quarantine so much. So this has made a huge impact and its wonderful to see her come back to be excited about something.

Visit link:

After nearly two years a 12-year-old girl with Cystic Fibrosis is getting her wish granted - KSNF/KODE - FourStatesHomepage.com

BETHESDA, Md.--(BUSINESS WIRE)--Today, the Cystic Fibrosis Foundation affirmed its support for the PASTEUR Act, a bipartisan proposal that, if passed, will support the development of new antibiotics and promote appropriate use of existing ones. The organization issued the following statement:

New solutions are needed now to bring novel antibiotics into the hands of patients. The Cystic Fibrosis Foundation applauds Senators Bennet and Young in reintroducing the Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act. If passed, the PASTEUR Act has the potential to spur vital investment into new antibiotics by addressing the economic disincentives that have long been associated with antibiotic development.

Routine use of antibiotics in cystic fibrosis care is medically necessary but unfortunately, too many people with CF find themselves battling difficult-to treat infections where existing antibiotics are not effective. However, antibiotic resistance is not solely a CF problemits a human problem that we can no longer ignore.

People with CF need more antibiotic options as do all Americans. The Foundation is making significant investments into the research and development of new approaches to address infections, but more is needed. Congress must take swift action to pass the PASTEUR Act, invigorating a new era of antibiotic research and development that could bring novel treatments into the hands of patients who need them the most.

For more information about the Foundations work in fighting antimicrobial resistance, visit cff.org.

About the Cystic Fibrosis Foundation

The Cystic Fibrosis Foundation is the world's leader in the search for a cure for cystic fibrosis. The Foundation funds more CF research than any other organization, and nearly every CF drug available today was made possible because of Foundation support. Based in Bethesda, Md., the Foundation also supports and accredits a national care center network that has been recognized by the National Institutes of Health as a model of care for a chronic disease. The CF Foundation is a donor-supported nonprofit organization. For more information, visit cff.org.

Original post:

The Cystic Fibrosis Foundation Affirms Support of the Introduction of the PASTEUR Act - Business Wire

Since its inaugural card in 2016, BRAVE CF has spearheaded 51 live events in five continents and has visited 22 different countries, including Russia, Sweden, Brazil, Saudi Arabia,United Arab Emirates, United Kingdom, Mexico, and the Philippines.

"The vision of His Highness Shaikh Khalid bin Hamad Al Khalifa was clear to us from the first day one, which is to reform the MMA industry from an event business to a sports business and to give opportunities to fighters around the world, regardless of marketability, language, nationality, or region. Talent would be the only variable,"saidcompany president Mohammed Shahid.

"We are witnessing his vision unfold today as we see the development of MMA all over Asia, Africa, South America. Now, it's showing in Europe," he continued.

BRAVE CF may have its roots in the Persian Gulf, but one of the company's missions is to globalize martial arts, and make the sport a part of the daily fabric of society wherever it stages a show.

In line with its strategy of building talents from the grassroots level, the promotion has signed more than 500 athletes from 70 different nations. In addition, it took advantage of venturing into untapped markets like India, Pakistan, Columbia, Romania, South Africa, Morocco and Jordan.

Aside from enlisting established names in MMA such as Ali Bagautinov, Jose "Shorty" Torres,Elias Boudegzdame, Zach Makovsky and Mohammad Fakhreddine, BRAVE CF has also been pivotal in the formation of local and homegrown stars such as Eldar Eldarov, Abdisalam Kubanychbek, Muhammad Mokaev and Jarrah Al-Silawi.

Moreover, staying true to its commitment to grow the sport, BRAVE CF partnered with IMMAF to hold the World Championships in 2019, giving amateur competitors a global platform to strut their wares.

''We have the best scouting program in the world, there's no doubt about it. That's because we connect with MMA people around the world, we connect with the gyms, with their national federations, with everyone involved in the sport. That's how you unearth the gems that we have," Shahid shared.

For 2021, Europe has been the center of BRAVE CF's attention, kicking off the year with an event in Sochi, Russia last January. The organization upped the ante last June 4th by holding its maiden show in Minsk, Belarus, catering 11 high-octane bouts that managed to feature six up-and-comers from the host nation.

"BRAVE CF has contributed so much to the reemergence of Belarus in MMA. Football, hockey, and basketball are the most popular sports in our country. But thanks to a promotion like BRAVE CF, the future of MMA in Belarus is secured," said Tatsiana Kukhareva, the director of Rukh Sport Management.

BRAVE CF recently announced that it is set to make its debut in Milan, Italyon August 1st, widening its footprint in Europe.

Olli "The Amazing" Santalahti, a European blue-chip recruit who inked an exclusive multi-bout contract with BRAVE CF earlier this year, is admittedly blown away by its aggressive expansion throughout the content.

"I can say that BRAVE CF is taking over Europe," Santalahti declared. "The fighters they are getting are high level. Though they originated from the Middle East, I think they are also the top European organization at the moment."

Given the Bahrain-based outfit's exponential growth, there also seems to be no signs of slowing down for BRAVE CF.

"The company is breaking records and making history towards the new age of MMA. It's an absolute honor to be a small part of this global vision," Shahid stated.

Media Contact:

Shaikha AlMawlaniEmail: [emailprotected]Contact number: +(973)-1700-0038

Photo: https://mma.prnewswire.com/media/1536508/BRAVE_CF_KHK_Sports.jpgPhoto: https://mma.prnewswire.com/media/1536509/BRAVE_CF_KHK_Sports.jpg

SOURCE Brave CF; KHK Sports

Go here to see the original:

BRAVE CF Looking To Introduce A New Age of MMA Through Royal Vision - PRNewswire

Global CF & CFRP Market is valued approximately USD 25.04 billion in 2018 and is anticipated to grow with a healthy growth rate of more than 10.40% over the forecast period 2019-2026.

Carbon fibre reinforced polymer/plastic is a light weight and strong material that is used in various industries such as aerospace & defense, wind energy, automotive, sporting goods, civil engineering, pipe & tank, marine, electrical & electronics and medical. Due to light weight property of carbon fibre and carbon fibre reinforcement plastics, aircraft manufacturers including Airbus and Boeing are adopting carbon fibre material to manufacture various components in order to reduce weight and increase fuel efficiency. Thus, the aerospace and aircraft industry is expected to contribute significantly in the growth of CF & CFRP market. Further, the increase in deployment of components made of carbon fibre material in automotive industry in order to achieve higher fuel efficiency is expected to create a lucrative growth in the CF & CFRP market.

For instance: in April 2017, Magna International Inc. announced that it is ready to revise the large structural parts it supplies out of carbon fiber. The increasing focus on producing electricity from renewable sources of energy has placed the carbon fibre reinforced plastic products on surging trend. Moreover, the growing demand for CF & CFRP materials from the emerging economies and the increasing potential opportunities in new applications are the few factors that are expected to create lucrative growth opportunities for the CF & CFRP market over the forecast period. However, high cost of production and the inability to reduce the cycle time are the factors likely to restrain the market growth.

Request for a FREE sample of this market research report@ https://www.reportocean.com/industry-verticals/sample-request?report_id=bw349

The regional analysis of global CF & CFRP Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region across the world in terms of market share owing to the increasing demand of superior performance products in the aerospace & defense industry, demand from Heavy-Duty Vehicle (HDV) and Medium-Duty Vehicle (MDV) for type-II and type-III CNG cylinders, ease of availability of raw materials for CFRP and other developmental strategies in the region. Whereas, Asia-Pacific is also anticipated to exhibit highest growth rate / CAGR over the forecast period 2019-2026. Factors such as increasing investments in renewable energy and rapidly growing aviation industry would create lucrative growth prospects for the Building Information Modeling (BIM) market across Asia-Pacific region.

Major market player included in this report are:Toray Industries Inc.Teijin LimitedMitsubishi Chemical Holdings CorporationSGL GroupFormosa Plastics CorporationHexcel CorporationHyosungTencateDowaksaCytec Solvay Group

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Raw Material Type:Polyacrylonitrile (Pan-Based) Carbon FibresPitch-Based Carbon FibreRayon-Based Carbon Fibre

By Resin Type:Thermosetting CFRPThermoplastic CFRP

By Manufacturing Process:Lay-Up ProcessCompression Molding ProcessResin Transfer Molding ProcessFilament Winding ProcessInjection Molding ProcessPultrusion ProcessOther Processes

By End-Use Industry:Aerospace & DefenseWind EnergyAutomotiveSporting GoodsCivil EngineeringPipe & TankMarineElectrical & ElectronicsMedicalOther Applications

By Region:North AmericaU.S.CanadaEuropeUKGermanyAsia PacificChinaIndiaJapanLatin AmericaBrazilMexicoRest of the World

Furthermore, years considered for the study are as follows:

Historical year 2016, 2017Base year 2018Forecast period 2019 to 2026

Send a request to Report Ocean to understand the structure of the complete report @https://www.reportocean.com/industry-verticals/sample-request?report_id=bw349

Target Audience of the Global CF & CFRP Market in Market Study:

Key Consulting Companies & AdvisorsLarge, medium-sized, and small enterprisesVenture capitalistsValue-Added Resellers (VARs)Third-party knowledge providersInvestment bankersInvestors

Excerpt from:

CF & CFRP Market demand with COVID-19 recovery analysis 2021 | better delivery process to boost market growth by 2026 The Manomet Current - The...